With human papillomavirus vaccine in short supply around, moving from a three- or two-dose regimen to one dose would immediately double or treble supplies, cut costs, and simplify logistics.

A careful study in Cancer by this week’s guest, Ana Rodriguez, and her colleagues adds to the evidence that single-dosing is possible and protective against pre-cancerous cervical lesions.

Cancer article

Cancer editorial 

An earlier (2015) podcast on the question of the number of vaccine doses needed to confer protection

Running time: 16 minutes